Moody Aldrich Partners LLC Purchases New Position in Evolent Health, Inc. (NYSE:EVH)

Moody Aldrich Partners LLC bought a new stake in shares of Evolent Health, Inc. (NYSE:EVH) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 50,259 shares of the technology company’s stock, valued at approximately $1,421,000.

A number of other institutional investors also recently bought and sold shares of the stock. Friedenthal Financial bought a new position in Evolent Health in the 3rd quarter valued at $723,000. Creative Planning grew its holdings in shares of Evolent Health by 139.1% in the third quarter. Creative Planning now owns 43,262 shares of the technology company’s stock worth $1,223,000 after purchasing an additional 25,171 shares during the last quarter. GAMMA Investing LLC grew its stake in Evolent Health by 5,365.5% in the 3rd quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company’s stock worth $45,000 after acquiring an additional 1,556 shares in the last quarter. Park Avenue Securities LLC purchased a new position in shares of Evolent Health during the third quarter worth approximately $212,000. Finally, SG Americas Securities LLC bought a new stake in shares of Evolent Health during the third quarter valued at approximately $891,000.

Evolent Health Stock Up 5.2 %

Shares of Evolent Health stock traded up $1.17 during trading on Thursday, hitting $23.57. 681,321 shares of the stock were exchanged, compared to its average volume of 1,614,502. The stock has a market cap of $2.74 billion, a price-to-earnings ratio of -18.86 and a beta of 1.56. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.08 and a quick ratio of 1.08. The firm’s 50-day moving average price is $28.58 and its 200 day moving average price is $25.44. Evolent Health, Inc. has a 12-month low of $17.98 and a 12-month high of $35.00.

Evolent Health (NYSE:EVH) last announced its quarterly earnings results on Thursday, August 8th. The technology company reported $0.30 EPS for the quarter, beating the consensus estimate of $0.21 by $0.09. Evolent Health had a negative net margin of 3.16% and a positive return on equity of 8.47%. The company had revenue of $647.10 million for the quarter, compared to analyst estimates of $636.46 million. During the same period in the prior year, the firm posted $0.06 earnings per share. The firm’s revenue was up 37.9% on a year-over-year basis. As a group, analysts forecast that Evolent Health, Inc. will post 0.86 earnings per share for the current fiscal year.

Insider Transactions at Evolent Health

In other Evolent Health news, CEO Seth Blackley sold 187,904 shares of the stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $30.00, for a total transaction of $5,637,120.00. Following the completion of the sale, the chief executive officer now directly owns 411,924 shares of the company’s stock, valued at approximately $12,357,720. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, General Counsel Jonathan Weinberg sold 42,140 shares of Evolent Health stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $31.20, for a total transaction of $1,314,768.00. Following the completion of the sale, the general counsel now directly owns 167,027 shares in the company, valued at approximately $5,211,242.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Seth Blackley sold 187,904 shares of the company’s stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $30.00, for a total transaction of $5,637,120.00. Following the completion of the sale, the chief executive officer now directly owns 411,924 shares in the company, valued at $12,357,720. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 307,291 shares of company stock worth $9,290,385. Insiders own 1.60% of the company’s stock.

Wall Street Analyst Weigh In

EVH has been the topic of a number of research reports. Truist Financial reissued a “buy” rating and set a $33.00 target price on shares of Evolent Health in a research report on Tuesday, August 27th. KeyCorp assumed coverage on Evolent Health in a report on Friday, October 11th. They set an “overweight” rating and a $35.00 price objective for the company. Stephens restated an “overweight” rating and set a $42.00 target price on shares of Evolent Health in a research note on Tuesday, July 30th. Royal Bank of Canada restated an “outperform” rating and set a $42.00 price target on shares of Evolent Health in a research note on Tuesday, October 8th. Finally, JMP Securities lowered their price target on Evolent Health from $34.00 to $31.00 and set a “market outperform” rating for the company in a research report on Friday, August 9th. Eleven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Evolent Health has an average rating of “Buy” and an average price target of $39.30.

Evolent Health Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.